Bladder Urothelial Carcinoma
About
Mappings
NCI Thesaurus: Bladder Urothelial Carcinoma (coding:ncit:C39851)
OncoTree: Bladder Urothelial Carcinoma (coding:oncotree:BLCA)
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | FGFR3 p.R248C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (2) | FGFR3 p.S249C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (2) | FGFR3 p.G370C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (2) | FGFR3 p.Y373C | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) FDA (2) | FGFR3::TACC3 | Bladder Urothelial Carcinoma | Erdafitinib | |
| EMA (1) | PD-L1 (CPS) >= 10 | Bladder Urothelial Carcinoma | Pembrolizumab | |
| EMA (1) | PD-L1 >= 1% | Bladder Urothelial Carcinoma | Nivolumab | |
| EMA (1) | PD-L1 >= 5% | Bladder Urothelial Carcinoma | Atezolizumab | |
| EMA (1) | FGFR3::BAIAP2L1 | Bladder Urothelial Carcinoma | Erdafitinib |